PDCD1 and metastatic melanoma: More recently, two clinical trials demonstrated that modulation of the gut microbiota with FMT from donors receiving anti-PD-1 who had a complete response to ICIs in refractory metastatic melanoma, was safe and capable of enhancing the efficacy of cancer therapies [27,28].